New Delhi: After Pfizer, the Serum Institute of India (SII) has sought permission from DCGI for emergency authorization of the corona vaccine. The Corona vaccine from Oxford and AstraZeneca is undergoing trial serum institute of India. The Serum Institute of India has become the first indigenous company to seek permission from DCGI for the Corona vaccine.

The Indian unit of American drug on Saturday maker Pfizer applied to the Indian drug regulator for formal approval of the emergency use of the Corona vaccine developed by it. Pfizer made this request after his Corona vaccine was approved in the UK and Bahrain. The Serum Institute in collaboration with the Indian Council of Medical Research (ICMR) on Sunday conducted a clinical trial of the third phase of the Corona vaccine 'Covishield' of Oxford in different parts of the country.

Citing Serum Institute's application, the company has stated that four data from the clinical trial have revealed that covicshield is quite effective in the case of patients with symptoms and especially severe corona patients. Two of the four test data belong to the UK while one each belongs to India and Brazil.

Also Read:

UK becomes the first country to roll out the Pfizer/BioNTech

BSP supremo Mayawati comes in support of farmer movement, says this in favor of 'Bharat Bandh'

Noida's Gautam Buddh Nagar imposes Section 144 till January 2